×
S&P 500   3,828.21 (+1.13%)
DOW   31,117.78 (+1.11%)
QQQ   281.20 (+0.33%)
AAPL   138.54 (+1.33%)
MSFT   259.36 (+0.99%)
META   159.82 (-0.89%)
GOOGL   2,170.65 (-0.40%)
AMZN   109.53 (+3.13%)
TSLA   677.28 (+0.57%)
NVDA   145.39 (-4.09%)
NIO   21.39 (-1.52%)
BABA   116.07 (+2.10%)
AMD   73.67 (-3.66%)
MU   53.45 (-3.31%)
CGC   2.81 (-1.40%)
T   21.37 (+1.96%)
GE   63.71 (+0.06%)
F   11.31 (+1.62%)
DIS   96.01 (+1.71%)
AMC   13.44 (-0.81%)
PFE   52.28 (-0.29%)
PYPL   71.30 (+2.09%)
NFLX   179.80 (+2.82%)
S&P 500   3,828.21 (+1.13%)
DOW   31,117.78 (+1.11%)
QQQ   281.20 (+0.33%)
AAPL   138.54 (+1.33%)
MSFT   259.36 (+0.99%)
META   159.82 (-0.89%)
GOOGL   2,170.65 (-0.40%)
AMZN   109.53 (+3.13%)
TSLA   677.28 (+0.57%)
NVDA   145.39 (-4.09%)
NIO   21.39 (-1.52%)
BABA   116.07 (+2.10%)
AMD   73.67 (-3.66%)
MU   53.45 (-3.31%)
CGC   2.81 (-1.40%)
T   21.37 (+1.96%)
GE   63.71 (+0.06%)
F   11.31 (+1.62%)
DIS   96.01 (+1.71%)
AMC   13.44 (-0.81%)
PFE   52.28 (-0.29%)
PYPL   71.30 (+2.09%)
NFLX   179.80 (+2.82%)
S&P 500   3,828.21 (+1.13%)
DOW   31,117.78 (+1.11%)
QQQ   281.20 (+0.33%)
AAPL   138.54 (+1.33%)
MSFT   259.36 (+0.99%)
META   159.82 (-0.89%)
GOOGL   2,170.65 (-0.40%)
AMZN   109.53 (+3.13%)
TSLA   677.28 (+0.57%)
NVDA   145.39 (-4.09%)
NIO   21.39 (-1.52%)
BABA   116.07 (+2.10%)
AMD   73.67 (-3.66%)
MU   53.45 (-3.31%)
CGC   2.81 (-1.40%)
T   21.37 (+1.96%)
GE   63.71 (+0.06%)
F   11.31 (+1.62%)
DIS   96.01 (+1.71%)
AMC   13.44 (-0.81%)
PFE   52.28 (-0.29%)
PYPL   71.30 (+2.09%)
NFLX   179.80 (+2.82%)
S&P 500   3,828.21 (+1.13%)
DOW   31,117.78 (+1.11%)
QQQ   281.20 (+0.33%)
AAPL   138.54 (+1.33%)
MSFT   259.36 (+0.99%)
META   159.82 (-0.89%)
GOOGL   2,170.65 (-0.40%)
AMZN   109.53 (+3.13%)
TSLA   677.28 (+0.57%)
NVDA   145.39 (-4.09%)
NIO   21.39 (-1.52%)
BABA   116.07 (+2.10%)
AMD   73.67 (-3.66%)
MU   53.45 (-3.31%)
CGC   2.81 (-1.40%)
T   21.37 (+1.96%)
GE   63.71 (+0.06%)
F   11.31 (+1.62%)
DIS   96.01 (+1.71%)
AMC   13.44 (-0.81%)
PFE   52.28 (-0.29%)
PYPL   71.30 (+2.09%)
NFLX   179.80 (+2.82%)
OTCMKTS:GNWSF

StageZero Life Sciences Stock Forecast, Price & News

$0.06
0.00 (0.00%)
(As of 06/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.06
$0.06
50-Day Range
$0.06
$0.09
52-Week Range
$0.00
$1.27
Volume
1,000 shs
Average Volume
26,719 shs
Market Capitalization
$4.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive GNWSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

GNWSF Stock Forecast (MarketRank)

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
StageZero Life Sciences logo

About StageZero Life Sciences (OTCMKTS:GNWSF)

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.

GNWSF Stock News Headlines

StageZero Life Sciences
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GNWSF
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

Net Income
$-6.86 million
Net Margins
-200.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.15 million
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Market Cap
$4.00 million
Optionable
Not Optionable
Beta
0.28














StageZero Life Sciences Frequently Asked Questions

How has StageZero Life Sciences' stock price performed in 2022?

StageZero Life Sciences' stock was trading at $0.2303 at the beginning of 2022. Since then, GNWSF stock has decreased by 72.4% and is now trading at $0.063450.
View the best growth stocks for 2022 here
.

Who are StageZero Life Sciences' key executives?

StageZero Life Sciences' management team includes the following people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Mr. Carl Solomon, Interim Chief Financial Officer
  • Prof. Choong-Chin Liew, Co-Founder
  • Mr. Warren Whitehead C.M.A., Chief Accountant (Age 69)
  • Mr. David Suria, Sr. Scientist

What is StageZero Life Sciences' stock symbol?

StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "GNWSF."

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is StageZero Life Sciences' stock price today?

One share of GNWSF stock can currently be purchased for approximately $0.06.

How much money does StageZero Life Sciences make?

StageZero Life Sciences (OTCMKTS:GNWSF) has a market capitalization of $4.00 million and generates $4.15 million in revenue each year.

How many employees does StageZero Life Sciences have?

StageZero Life Sciences employs 51 workers across the globe.

How can I contact StageZero Life Sciences?

StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The official website for StageZero Life Sciences is www.stagezerolifesciences.com. The company can be reached via phone at 905-209-2030 or via email at [email protected].

This page (OTCMKTS:GNWSF) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.